We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00412646
Recruitment Status : Completed
First Posted : December 18, 2006
Last Update Posted : April 28, 2010
Information provided by:
Tibotec Pharmaceuticals, Ireland